切换至 "中华医学电子期刊资源库"
高级检索
中华乳腺病杂志(电子版)

中华乳腺病杂志(电子版) ›› 2013, Vol. 07 ›› Issue (06) : 411 -414. doi: 10.3877/cma. j. issn.1674-0807.2013.06.004

论著

人类白细胞分化抗原133 与乳腺浸润性导管癌临床病理特征的关系
宋云骏1, 姜林鹤1, 冷彦利1, 刘运江1,†()   
  1. 1.067000 河北省承德市肿瘤医院肿瘤外科承德市肿瘤防治中心
  • 收稿日期:2013-06-03 出版日期:2013-12-01
  • 通信作者: 刘运江
  • 基金资助:
    承德市科学技术研究与发展计划项目(20122186)

Relationship between CD133 expression and the clinicopathological characteristics of breast invasive ductal carcinoma

Yun-jun SONG1, Lin-he JIANG1, Yan-li LENG1, Yun-jiang LIU†,1()   

  1. 1.Department of Oncological Surgery, Tumour Hospital of Chengde City, Chengde 067000, China
  • Received:2013-06-03 Published:2013-12-01
  • Corresponding author: Yun-jiang LIU
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

宋云骏, 姜林鹤, 冷彦利, 刘运江. 人类白细胞分化抗原133 与乳腺浸润性导管癌临床病理特征的关系[J/OL]. 中华乳腺病杂志(电子版), 2013, 07(06): 411-414.

Yun-jun SONG, Lin-he JIANG, Yan-li LENG, Yun-jiang LIU. Relationship between CD133 expression and the clinicopathological characteristics of breast invasive ductal carcinoma[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2013, 07(06): 411-414.

目的

研究肿瘤干细胞标志物人类白细胞分化抗原(CD)133 在乳腺浸润性导管癌组织中的表达及其与临床病理因素之间的关系。

方法

收集2001年1月至2005年12月间承德市肿瘤医院和承德医学院附属医院肿瘤科的102 例乳腺浸润性导管癌组织,采用免疫组织化学方法检测其CD133蛋白表达,并用χ2 检验或Fisher 确切概率法分析CD133 表达与临床病理因素的关系。

结果

乳腺浸润性导管癌组织不同程度地表达CD133。 不同肿瘤直径组间CD133 阳性表达率差异有统计学意义(χ2=7.476,P=0.024),其中肿瘤直径＞2 ～5 cm 组CD133 阳性表达率明显高于肿瘤直径≤2 cm 组[56.72%(38/67)比26.09%(6/23),χ2=6.429,P＜0.012]。 不同组织学分级间相比,CD133 阳性表达率的差异也有统计学意义(χ2=6.274,P=0.043)。 并且,有淋巴结转移者CD133 阳性表达率比无淋巴转移者高[64.71%(22/34)比39.71%(27/68),χ2=5.675,P=0.017)]。 乳腺浸润性导管癌组织中,CD133 阳性表达率在不同年龄、不同临床分期之间差异无统计学意义(χ2=0.177,P=0.674;χ2=2.874, P=0.242)。

结论

CD133 有可能作为判断乳腺浸润性导管癌侵袭转移的指标。

关键词: 肿瘤干细胞, 抗原,CD, 癌,导管,乳腺, 免疫组织化学

Objective

To investigate the expression of cancer stem cell marker CD133 in breast invasive ductal carcinoma and its relationship with the clinicopathological parameters.

Methods

Totally 102 cases of invasive ductal carcinoma in the Tumour Hospital of Chengde City and Department of Oncology, the Affiliated Hospital of Chengde Medical College from January 2001 to December 2005 were involved, and CD133 protein expressions in their carcinoma tissues were detected by immunohistochemistry. χ2 test or Fisher probabilities test was used to analyze the relationship of CD133 expression and clinicopathological parameters.

Results

CD133 was expressed to different extents in the breast invasive ductal carcinoma tissues. The positive expression rate of CD133 showed statistical significant difference between groups with different tumor sizes(χ2=7.476,P=0.024),and the positive expression rate of CD133 in the patients with tumor diameter of ＞2-5 cm was significantly higher than that in the patients with tumor diameter≤2 cm [56.72%(38/67)vs 26.09%(6/23),χ2=6.429,P＜0.012]. There were some statistical differences between groups at different histological grades(χ2=6.274,P=0.043).The positive expression rates of CD133 in patients with lymph node metastasis were significantly higher than those without [64.71%(22/34) vs 39.71%(27/68),χ2=5.675,P=0.017].There was no significant difference in the expression of CD133 between groups with different age and dinical stage(χ2=0.177,P=0.674;χ2=2.874,P=0.242).

Conclusion

CD133 can be used as an important marker of invasion and metastasis in breast invasive ductal carcinoma.

Key words: Neoplastic stem cells, Antigens,CD, Carcinoma,ductal,breast, Immunohistochemistry
图1 乳腺浸润性导管癌的病理表现(HE ×200)
图2 乳腺浸润性导管癌中CD133 免疫组织化学染色结果 a:CD133 阳性表达(SP ×400) b: CD133 阳性表达(SP ×200);c: CD133 阴性表达(SP ×100)
表1 乳腺浸润性导管癌CD133 蛋白表达与临床病理因素的关系
病理因素 例数 CD133表达(例) χ 2值 P值
阳性 阴性
年龄 0.177 0.674
＜50岁 54 27 27
≥50岁 48 22 26
肿瘤直径 7.476 0.024
≤2 cm 23 6 17
＞2～5 cm 67 38a 29
＞5 cm 12 4 8
临床分期 2.874b 0.242
Ⅰ 8 2 6
Ⅱ 35 15 20
Ⅲ 59 32 27
组织学分级 6.274 0.043
Ⅰ 15 5 10
Ⅱ 57 24 33
Ⅲ 30 20 10
淋巴结转移 5.675 0.017
有 34 22 12
无 68 27 41
[1]
UICC. TNM classification of malignant tumors [M]. 6th ed.Hoboken: John Wiley & Sons,2002:131-142.
[2]
Horst D, Kriegl L, Engel J, et al. CD133 expression is an independent prognostic marker for low survival in colorectal cancer[J] Br J Cancer,2008,99(8):1285-1289.
[3]
李博艳,李春国.125 例乳腺浸润性导管癌预后因素分析[J]. 内蒙古中医药,2012,31(1):39-40.
[4]
Smith LM, Nesterova A, Ryan MC, et al. CD133/ prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers[J]. Br J Cancer,2008,99(1):100-109.
[5]
吴明霞, 邓海贞, 顾永平,等. 肿瘤干细胞标志物CD133 在乳腺癌组织中的表达及其临床意义[J]. 苏州大学学报(医学版),2009,29(4):678-680,693.
[6]
Abraham BK, Fritz P, McClellan M, et al. Prevalence of CD44 +/CD24 -/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis[J]. Clin Cancer Res,2005,11(3):1154-1159.
[7]
Croker AK, Allan AL. Inhibition of aldehyde dehydrogenase(ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44 human breast cancer cells[J].Breast Cancer Res Treat,2012,133(1):75-87.
[8]
Luo D, Yan X, Liu D, et al. Differential effects of mesenchymal stem cells on a heterogeneous cell population within lung cancer cell lines[J]. Mol Cell Biochem, 2013,378(1/2):107-116.
[9]
Mizugaki H, Sakakibara-Konishi J, Kikuchi J, et al. CD133 expression:a potential prognostic marker for non-small cell lung cancers[EB/OL]. [2013-05-30]. http:/ /link.springer. com/article/10.1007%2Fs10147-013-0541-x#page-2.
[10]
O’Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice[J]. Nature,2007,445(7123):106-110.
[11]
Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells [J].Nature,2007,445(7123):111-115.
[12]
Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer[J]. Cell Stem Cell,2007,1(3):313-323.
[13]
Smith LM, Nesterova A, Ryan MC, et al. CD133/ prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers[J]. Br J Cancer,2008,99(1):100-109.
[14]
Liu Q, Li J, Zheng X, et al. Expression of CD133, PAX2,ESA,and GPR30 in invasive ductal breast carcinomas[J].Chin Med J(Engl),2009,122(22):2763-2769.
[15]
Currie MJ, Beardsley BE, Harris GC, et al.Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity[J]. Hum Pathol,2013,44(3):402-411.
[1] 赵阳, 肖迎聪, 巨艳, 党晓智, 蔡林利, 薛文欣, 李洋, 肖瑶, 郭妤绮, 宋宏萍. 自动乳腺超声联合免疫组化早期预测乳腺癌新辅助化疗病理完全缓解的临床价值[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(04): 361-369.
[2] 武壮壮, 张晓娟, 史泽洪, 史瑶, 原韶玲. 超声联合乳腺X线摄影及PR、Her-2预测高级别与中低级别乳腺导管原位癌的价值[J/OL]. 中华医学超声杂志（电子版）, 2023, 20(06): 631-635.
[3] 贺媛媛, 李佳, 杨红. 宫颈中肾腺癌1例并文献复习[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(01): 97-104.
[4] 韩春颖, 王婷婷, 李艳艳, 朴金霞. 子宫内膜癌患者淋巴管间隙浸润预测因素研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 403-409.
[5] 刘星辰, 刘娟, 魏宝宝, 刘洁, 刘辉. XIAP与XAF1异常表达与卵巢癌的相关性分析[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 419-427.
[6] 唐冬梅, 周胜兰, 胡正昌, 邱小明, 宿宓, 熊雯, 魏璐, 范从红, 魏素梅, 罗丹. 妊娠合并恶性间皮瘤1例并文献复习[J/OL]. 中华妇幼临床医学杂志(电子版), 2022, 18(06): 722-730.
[7] 陈怡芳, 黄晓卉. 肝细胞癌中对氧磷酶2的表达及临床意义[J/OL]. 中华普通外科学文献(电子版), 2024, 18(03): 186-191.
[8] 刘政宏, 王凤力, 吉亚君, 高佳. 胃癌中ELK3蛋白的表达与临床病理特征和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(02): 155-159.
[9] 郭伟林, 李运涛, 尚培中, 李晓武, 李伟. 胰腺癌S100A4和Midkine表达研究[J/OL]. 中华普外科手术学杂志(电子版), 2023, 17(02): 149-152.
[10] 甘开梅, 黄剑. 肺癌干细胞对EGFR-TKI耐药影响的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2023, 13(01): 36-44.
[11] 李峻峰, 李军, 孙勤丰, 孙建光, 孔祥兴. 九例结肠髓样癌的临床病理特征分析[J/OL]. 中华结直肠疾病电子杂志, 2023, 12(03): 248-252.
[12] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[13] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[14] 毛高才, 张建波, 袁一方, 毛小波, 戴慧勇, 王哲. 耳后淋巴结内涎腺透明细胞型嗜酸性腺瘤的诊断学特征[J/OL]. 中华诊断学电子杂志, 2023, 11(04): 261-265.
[15] 刘迎, 尹嫚, 杨林青, 王云飞. 子宫颈浸润性复层产黏液的癌的诊断学特征并文献复习[J/OL]. 中华诊断学电子杂志, 2023, 11(03): 173-177.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号